By adhering to inflammatory white blood cells and leveraging their natural tropism, CP@CM effectively delivers celecoxib to inhibit COX-2, reduce immunosuppressive cell recruitment, and increase CD8+ and CD4+ T cell infiltration at the tumor site, reversing the immunosuppressive microenvironment and enhancing postoperative immunotherapy outcomes [120]. This evidence concerns the gene CD4 and neoplasm.